drugset / Trial / NCT02067299

A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants

NCT02067299

Phase 1 Completed 20 enrolled Janssen Research & Development, LLC
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate effect of JNJ-42847922 on sleep latency (latency to persistent sleep) in participants with major depressive disorder who are stably treated with selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor who suffer from insomnia (inability to fall asleep).

Timeline

Start
2014-02
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule 10 mg Oral
Subject Seltorexant Small molecule 20 mg Oral
Subject Seltorexant Small molecule 40 mg Oral